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ABSTRACT 
Increased fracture risk has been associated with weight loss in postmenopausal women but the time course 
over which this occurs has not been established. The aim of this study was to examine the effects of 
unintentional weight loss of ≥10 lb (4.5 kg) in postmenopausal women on fracture risk at multiple sites up 
to 5 years following weight loss. Using data from the Global Longitudinal Study of Osteoporosis in Women 
(GLOW) we analyzed the relationships between self-reported unintentional weight loss of ≥10 lb at 
baseline, year 2, or year 3 and incident clinical fracture in the years following weight loss. Complete data 
were available in 40,179 women (mean age ± SD 68 ± 8.3 years). Five-year cumulative fracture rate was 
estimated using the Kaplan-Meier method, and adjusted hazard ratios for weight loss as a time-varying 
covariate were calculated from Cox multiple regression models. Unintentional weight loss at baseline was 
associated with a significantly increased risk of fracture of the clavicle, wrist, spine, rib, hip, and pelvis for 
up to 5 years following weight loss. Adjusted hazard ratios showed a significant association between 
unintentional weight loss and fracture of the hip, spine, and clavicle within 1 year of weight loss, and these 
associations were still present at 5 years. These findings demonstrate increased fracture risk at several sites 
after unintentional weight loss in postmenopausal women. This increase is seen as early as 1 year following 
weight loss, emphasizing the need for prompt fracture risk assessment and appropriate management to 
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Introduction 
Body mass index (BMI) is a major determinant of bone mineral density (BMD) and low BMI is a well-
recognized risk factor for fragility fracture.
(1)
 Weight loss is associated with accelerated bone loss and 
increased risk of fracture in postmenopausal women. In women enrolled in the Study of Osteoporotic 
Fractures, weight loss of ≥10% was associated with a 68% increase in the risk of non-spine fracture 
(defined as hip, pelvis, and humerus) over an average follow-up of 19.5 months.
(2)
 In a subsequent study 
with longer follow-up in the same cohort, a two-fold increase in the risk of hip fracture was demonstrated.
(3)
 
Increased risk of hip fracture associated with weight loss has also been reported in other US populations 
(relative risks 2.9 and 2.37)
(4,5)
; and in a prospective population-based study from Norway, weight loss of 
≥5% was associated with a significant increase of 33% in the risk of distal radius fracture.(6) In a recent 
post-hoc analysis from the Women’s Health Initiative Observational Study and Clinical Trials with a mean 
follow-up period of 11 years, weight loss of ≥5% was associated with increased risk of fracture of the hip 
(65%), upper limb (9%), and central body (hip, spine, or pelvis) (30%). When women with unintentional 
versus intentional weight loss were considered separately, significantly higher incidence rates of both hip 
(33%) and vertebral (16%) fracture were demonstrated in the former group.
(7)
 The association of weight loss 
with hip, wrist, and vertebral fractures in these studies is consistent with the inverse correlation between 
BMI and fracture at these sites.
(8)
 
 These studies provide a growing body of evidence that weight loss after the menopause is 
associated with increased fracture risk, particularly at the hip but also at other sites. However, the follow-up 
period of these studies has ranged from 19.5 months to 11 years and the time course over which fractures 
occur in relation to weight loss has not been clearly established; in particular, it is uncertain how rapidly 
fracture risk increases following weight loss. The aim of the present study was to investigate the effects of 
unintentional weight loss in postmenopausal women on the incidence and time course of clinical fractures at 
multiple sites in the 5 years following self-reported weight loss. 
 
Materials and Methods 
GLOW is a prospective cohort study involving 723 physician practices at 17 sites in 10 countries (Australia, 
Belgium, Canada, France, Germany, Italy, Netherlands, Spain, UK, and USA). The study methods have 
been reported.
(9)
 In brief, practices typical of each region were recruited through primary care networks 
organized for administrative, research, or educational purposes, or by identifying all physicians in a 
geographic area. Each site obtained local ethics committee approval to participate in the study. The 
practices provided the names of women aged ≥55 years who had been seen by their physician in the past 24 
months. After exclusion of women due to cognitive impairment, language barriers, institutionalization, or 
who were too ill, 60,393 women agreed to participate in the study. 
 
Data collection 
All data for the study were self-reported, using self-administered questionnaires mailed at baseline and 
years 1, 2, 3, and 5 and covered domains that included patient characteristics and risk factors for fracture, 
fracture history, current medication use, and other medical diagnoses.  
Information was collected at baseline on history of previous fractures (that had occurred since the age of 45 
years), and incident fractures were assessed during the 1-, 2-, 3-, and 5-year follow-up surveys. All surveys 
included details of fracture location, including spine, hip, wrist, clavicle, upper arm/shoulder, rib, pelvis, 
ankle, upper leg, and lower leg.   
 Unintentional weight loss was defined as a “yes” response to the question: “In the last 12 months, 
have you lost 10 or more pounds without trying?” This question appeared on the baseline and the year 2 and 
year 3 follow-up surveys. Incident fracture data were collected on all follow-up GLOW surveys, including 
the fracture site and date. A fracture was considered associated with unintentional weight loss if it occurred 
at any time after the survey date when weight loss was reported, with a separate analysis for fracture within 
365 days after the weight loss survey (if fracture occurred >365 days after weight loss, the fracture was not 
considered to be associated with weight loss).  
Subjects were considered to be taking anti-osteoporosis medication if they reported current use of 
alendronate, calcitonin, estrogen, etidronate, ibandronate, pamidronate, recombinant human parathyroid 
hormone (1–84), raloxifene, risedronate, strontium ranelate, teriparatide, tibolone or zoledronic acid. 
Information was also obtained about comorbid conditions including asthma, emphysema, osteoarthritis, 
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rheumatoid arthritis, colitis, stroke, high cholesterol, hypertension, Parkinson’s disease, multiple sclerosis, 
cancer, and type 1 diabetes. Health-related quality of life and functional status were assessed using the 
EuroQoL EQ-5D tool
(10)
 and the vitality and physical function sections of the SF-36 health survey.
(11)
 
Mortality data were not obtained in GLOW participants and it was therefore not possible to distinguish 




Weight loss of ≥10 lb (4.5 kg) was assessed at baseline and follow-up years 2 and 3. Fracture was assessed 
at all surveys (baseline and follow-up years 1, 2, 3, and 5, where year 5 included fracture in years 4 and 5). 
The primary endpoint was time to first fracture between 0 and 5 years after baseline, for each of 10 bone 
sites and their composite (denoted ‘any fracture’). A secondary endpoint was time to first fracture within 1 
year of weight loss. 
Baseline characteristics of women with involuntary weight loss ≥10 lb at any of the three surveys were 
compared to those with no weight loss, using the chi-square test for discrete, and Wilcoxon rank sum test 
for continuous variables. 
 Three sets of unadjusted and two sets of adjusted analyses were performed. Unadjusted analyses: 
(1) rates of 5-year fracture were computed using the Kaplan-Meier method, for women with and without 
baseline weight loss. Rates in the two groups were compared using the log-rank test; (2) hazard ratios (HRs) 
and 95% confidence intervals (CIs) were calculated for 5-year fracture and the covariate of baseline weight 
loss, using the Cox model; (3) as in (2), for weight loss at any time treated as a time-varying covariate 
(TVC). Adjusted analyses: (4) using the Cox model, HRs and 95% CIs were calculated for 5-year fracture 
and the TVC of weight loss at any time, adjusted for any Table 1 factors which changed unadjusted weight 
loss HRs (on the log scale) by ≥10%. Backwards elimination of covariates was performed until only 
covariates whose p-value was ≤0.20 remained. Covariate elimination was performed independently for each 
of the 11 fracture outcomes; (5) HRs and 95% CIs for 1-year fracture and the TVC of weight loss at any 
time, adjusted as in (4).  




The numbers of women who completed the baseline and follow-up surveys at years 1, 2, 3, and 5 were 
60,393, 51,490, 48,750, 45,490, and 38,411, respectively. Complete data on weight loss at baseline and 
years 2 and 3 and on fracture through to year 3 were available in 40,179 women aged 68 ± 8.3 (mean ± SD) 
years. Of these, 33,471 women also had year 5 fracture information. Median follow-up time for the 3897 
women with any fracture was 713 days (2.0 years). Median follow-up for the women with no fracture was 
1685 days (4.6 years). Unintentional weight loss of ≥10 lb was reported by 3124 (7.8%) women at baseline, 
3149 (7.8%) in year 2, and 3070 (7.6%) in year 3. Baseline characteristics of women according to weight 
loss are shown in Table 1. Women with unintentional weight loss were significantly older, with poorer 
physical function and quality-of-life indices, and greater frequency of falls. They were also more likely to 
have a history of fracture, to use anti-osteoporosis medication or glucocorticoids, and to have comorbid 
conditions.  
 Cumulative 5-year fracture rate estimates according to baseline weight loss are shown for all 
fracture sites in Table 2 and for hip and spine in Figure 1. Significant increases were seen in women with 
unintentional weight loss versus women without weight loss for any fracture and for fracture of the clavicle, 
wrist, spine, rib, hip and pelvis. The association between weight loss and subsequent fracture was 
proportional over the study period in all cases except for spine fracture, where the association was stronger 
in the first year after weight loss (p=0.02; proportional hazards assumption test). 
  Unadjusted and adjusted HRs between unintentional weight loss and fracture are shown in Table 3. 
Details of the adjusted models are shown in Supplementary Tables 1–11. After adjustment, a significant 
increase in risk of fracture was seen for any fracture, clavicle, hip, and spine fracture both at 5 years and 
within 1 year of unintentional weight loss.  
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Discussion 
Our results confirm previous reports of an association between weight loss and increased fracture risk in 
postmenopausal women
(2-7)
 and add novel information about the time frame in which fracture occurs 
relative to weight loss. We have shown for the first time that fracture risk at the hip, spine, and clavicle 
increases significantly within 1 year following the year in which unintentional weight loss was reported and 
that the cumulative risk of these fractures, as well as those of the wrist, rib, and pelvis is significantly 
increased at 5 years of follow-up. 
 Previous studies of the effects of weight loss on fracture risk have differed in their time frame of 
weight loss and of follow-up, and have also varied in their definition of weight loss.
(2-7)
 All have included 
women with a history of weight loss over a number of years, ranging from 3 to 20 or more, and the average 
duration of follow-up has ranged from 19.5 months to 22 years. Our study is unique in that we could assess 
the time course of the effect of unintentional weight loss on fracture rate over a 5-year period. Most other 
studies defined weight loss in percentage rather than in absolute terms, some using a criterion of ≥5% and 
others ≥10% of baseline body weight. All of these studies used measured weight rather than self-reported 
weight as in our study. Notwithstanding these differences, our results are consistent with those previously 
reported, with increased risk of hip fracture,
(3-5,7)




 and wrist fracture
(6)
 in 
association with unintentional weight loss. An association between unintentional weight loss and fracture of 
the clavicle has not been previously reported. 
 In our questionnaire we included information only about unintentional, not intentional, weight loss. 
The distinction is important because unintentional weight loss is often associated with coexisting conditions 
that may independently cause increased bone loss and fracture risk. In addition, whereas unintentional 
weight loss may start from any baseline weight, intentional weight loss is more likely to be seen in 
overweight or obese women. In the study of Crandall et al,
(7)
 different fracture site profiles were seen in 
women with unintentional and intentional weight loss, the former being associated with increased risk of 
hip and spine fracture and the latter with increased risk of ankle fracture but decreased risk of hip fracture. 
As expected, in the present study lower baseline BMI was a significant independent contributor to fracture 
risk at most sites, although for upper arm and lower limb fractures there was a positive association between 
baseline BMI and fracture risk. Both sets of results are consistent with the known site-specificity of the 
relationship between BMI and fracture risk,
(8)
 low BMI being a strong risk factor for hip and spine fracture 
and obesity being associated with decreased risk of hip fracture and increased risk of ankle and upper arm 
fractures.
(8,12-16)
 However, in the study of Ensrud et al. both intentional and unintentional weight loss were 
associated with increased risk of hip fracture.
(3)
 The adverse effects of intentional weight loss on BMD in 
obese adults can be attenuated by exercise-training programs, but the feasibility and effectiveness of this 
approach in older adults with unintentional weight loss has not been investigated.
(17)
 
 A number of mechanisms may underlie the association between unintentional weight loss and 
increased fracture risk. Weight loss, whether unintentional or intentional, is associated with increased rates 
of bone loss, particularly at the hip
(18-21)
 and reflects, at least in part, a physiological response to decreased 
mechanical loading. Co-morbid conditions may contribute as a result of decreased mobility, medications 
such as aromatase inhibitors and glucocorticoids, and increased production of pro-inflammatory, pro-
resorptive cytokines.  Co-morbidities that were significant on a univariate level were included in the 
multivariable analysis. Weight loss is also associated with reduced muscle mass and strength, resulting in 
increased risk of falling, reduced protective responses to falling, and reduced padding from subcutaneous 
tissue.  
 Our study has several strengths, including the large sample size, prospective design, and 
international representation. There are also some limitations. GLOW is a practice‐ based rather than a 
population‐ based study and is therefore subject to bias both in the selection of physicians and in the 
sampling and recruitment of patients. All data were collected by patient self‐ report and may be limited by 
recall inaccuracies and measurement error with regard to reported weight loss. Studies that have examined 
the validity of self‐ reported fractures have shown reasonable accuracy for fractures of the hip, wrist, and 
humerus but lower sensitivity for rib, ankle, and clinical vertebral fractures 
(22-25)
; however, in addition, 
subclinical vertebral fractures are likely to be under-reported. We believe that the generalizability of our 
findings to clinical practice in the general population is likely to be good, but cannot exclude possible 
effects of sampling bias and inaccuracies resulting from self‐ report of fractures and weight loss. As data on 
mortality were not available in GLOW, higher mortality rates in women with unintentional weight loss may 
have resulted in underestimation of fracture risk. Finally, only women were included in the study. 
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 In conclusion, the results of our study indicate that unintentional weight loss in postmenopausal 
women is associated with increased fracture risk at several sites. The increased fracture risk in the hip, 
spine, and clavicle was independent of underlying diseases included in the questionnaire, as well as other 
risk factors associated with fracture at different sites. Finally, an increase in fracture risk is seen within the 
year following weight loss and persists for at least 5 years. Our findings emphasize the need for prompt 
assessment and appropriate management strategies in such women in order to reduce the risk of fracture. 
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Fig. 1. Kaplan-Meier curves showing cumulative (A) hip and (B) spine fracture rates over 5 years, by 
baseline weight loss in postmenopausal women.  
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Table 1. Baseline Characteristics of GLOW Women by Unintentional Weight Loss  
Variable Unintentional loss of ≥10 lb (4.5 kg)  







Age, years 66 (60–73) 69 (62–76) <0.0001 
Body mass index, kg/m
2
 26 (23–29) 27 (23–31) <0.0001 
SF-36 physical function 85 (70–95) 70 (44–90) <0.0001 
SF-36 vitality 63 (50–75) 56 (44–69) <0.0001 
EQ-5D index 0.83 (0.76–1.00) 0.79 (0.68–0.83) <0.0001 
Medical history    
Fracture since age 45 years 6757 (21) 1931 (27) <0.0001 
Early menopause 4253 (13) 1388 (19) <0.0001 
Maternal history of hip fracture 4224 (13) 913 (13) 0.91 
Current smoker 2387 (7.3) 844 (12) <0.0001 
Alcohol (≥21 drinks/week) 170 (0.5) 32 (0.4) 0.46 
Falls in past 12 months   <0.0001 
0 21173 (65) 4029 (56)  
1 7447 (23) 1752 (24)  
≥2 4030 (12) 1427 (20)  
Medication use    
Anti-osteoporosis medication 6174 (19) 1442 (21) 0.01 
Estrogen 3044 (9.3) 619 (8.6) 0.05 
Calcium  14755 (45) 3083 (43) 0.0001 
Cortisone or prednisone 737 (2.3) 345 (4.8) <0.0001 
Vitamin D  14410 (45) 3141 (44) 0.39 
Co-existing condition    
Asthma 3340 (10) 1079 (15) <0.0001 
Cancer 4382 (13) 1208 (17) <0.0001 
Celiac disease 202 (0.6) 49 (0.7) 0.51 
Chronic bronchitis or emphysema 2104 (6.5) 866 (12) <0.0001 
Diabetes (type 1) 756 (2.3) 412 (5.7) <0.0001 
Heart disease 3733 (12) 1414 (20) <0.0001 
High cholesterol  16156 (50) 3829 (53) <0.0001 
Hypertension 15289 (47) 4168 (58) <0.0001 
Multiple sclerosis 182 (0.6) 63 (0.9) 0.003 
Osteopenia 5973 (19) 1023 (15) <0.0001 
Osteoporosis 6083 (19) 1777 (26) <0.0001 
Parkinson’s disease 85 (0.3) 86 (1.2) <0.0001 
Rheumatoid arthritis 221 (0.7) 93 (1.3) <0.0001 
Stroke 892 (2.7) 407 (5.7) <0.0001 
Ulcerative colitis or Crohn’s disease 524 (1.6) 229 (3.2) <0.0001 
Geographic region   <0.0001 
Canada/Australia 4543 (13) 1057 (14)  
Europe 13,298 (40) 2413 (33)  
USA 15,045 (46) 3823 (52)  
Physical function    
General health fair or poor 5234 (16) 2123 (29) <0.0001 
Need arms to assist in standing 8544 (26) 3304 (46) <0.0001 




 percentiles) or frequency (percentage).  
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Table 2. Cumulative 5-Year Fracture Rate Estimates according to Baseline Weight Loss (Unintentional 
Weight Loss Versus no Unintentional Weight Loss) 
Fracture location # of 
fractures 




Weight loss  
(n=3124) 
No weight loss 
(n=37,055) 
Any fracture 3897 15 10 <0.0001 
Clavicle 161 1.3 0.4 <0.0001 
Upper arm 404 1.4 1.1 0.11 
Wrist 1130 3.9 3.1 0.03 
Spine 521 2.5 1.4 <0.0001 
Rib 705 3.0 2.0 <0.0001 
Hip 350 2.0 0.9 <0.0001 
Pelvis 206 2.4 1.4 0.01 
Ankle 670 2.3 1.9 0.07 
Upper leg 180 0.6 0.5 0.22 
Lower leg 287 0.8 0.8 0.78 
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Table 3.  Unadjusted and Adjusted Associations between Unintentional Weight Loss and Fracture (hazard 
ratio and 95% confidence interval for weight loss) 




within 5 years 
Weight loss at 
baseline, year 2, or 
year 3* (unadjusted), 
and fracture within  
5 years   
Weight loss at 
baseline, year 2, 
or year 3* 
(adjusted†), 
and fracture 
within 5 years 
Weight loss at 
baseline, year 2, or 
year 3* (adjusted†), 
and fracture within  
1 year 
Any fracture 
of the 10 
listed bones 
1.49 (1.34–1.65) 1.45 (1.33–1.58) 1.15 (1.05–1.27) 1.15 (1.00–1.33) 
Clavicle 3.07 (2.08–4.52) 2.70 (1.89–3.86) 1.81 (1.22–2.70) 1.72 (1.00–2.96) 
Upper arm 1.31 (0.94–1.82) 1.31 (0.99–1.73) 0.97 (0.72–1.32) 1.24 (0.84–1.85) 
Wrist 1.24 (1.02–1.52) 1.16 (0.97–1.38) 0.98 (0.80–1.20) 0.97 (0.72–1.31) 
Spine 1.99 (1.55–2.55) 2.08 (1.69–2.57) 1.41 (1.13–1.77) 1.63 (1.19–2.23) 
Rib 1.59 (1.26–2.00) 1.53 (1.25–1.86) 1.05 (0.84–1.32) 1.14 (0.82–1.59) 
Hip 2.13 (1.59–2.85) 2.32 (1.82–2.97) 1.57 (1.21–2.05) 1.59 (1.09–2.33) 
Pelvis 1.55 (1.00–2.39) 1.47 (1.02–2.14) 0.93 (0.61–1.41) 0.85 (0.45–1.59) 
Ankle 1.28 (0.98–1.65) 1.31 (1.05–1.63) 1.10 (0.87–1.40) 1.03 (0.72–1.47) 
Upper leg 1.35 (0.83–2.20) 1.49 (0.99–2.24) 0.90 (0.58–1.39) 1.19 (0.68–2.07) 
Lower leg 1.06 (0.70–1.63) 1.00 (0.69–1.45) 0.77 (0.52–1.14) 0.78 (0.43–1.42) 
*Weight loss treated as a time-varying covariate. 
†Adjusted for set of all Table 1 factors which, individually, change weight loss estimate ≥10%, and which, 
after backwards elimination, have p≤0.20 in adjusted final model.   
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Figure 1 
 
